BMRN vs. TEM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BMRN and TEM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BMRN | TEM |
|---|---|---|
| Company Name | BioMarin Pharmaceutical Inc. | Tempus AI, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 10.50 billion USD | 12.05 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | July 26, 1999 | June 14, 2024 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BMRN and TEM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BMRN | TEM |
|---|---|---|
| 5-Day Price Return | 3.91% | -4.60% |
| 13-Week Price Return | -4.88% | -7.18% |
| 26-Week Price Return | -8.45% | -0.62% |
| 52-Week Price Return | -17.90% | 0.59% |
| Month-to-Date Return | 2.17% | -23.78% |
| Year-to-Date Return | -16.74% | 102.84% |
| 10-Day Avg. Volume | 2.36M | 7.32M |
| 3-Month Avg. Volume | 2.29M | 8.96M |
| 3-Month Volatility | 26.60% | 66.82% |
| Beta | 0.27 | 2.31 |
Profitability
Return on Equity (TTM)
BMRN
8.84%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
BMRN’s Return on Equity of 8.84% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
TEM
-67.96%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
TEM has a negative Return on Equity of -67.96%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
BMRN
16.82%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
BMRN’s Net Profit Margin of 16.82% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
TEM
-18.45%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
TEM has a negative Net Profit Margin of -18.45%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
BMRN
19.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
BMRN’s Operating Profit Margin of 19.89% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
TEM
-23.00%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
TEM has a negative Operating Profit Margin of -23.00%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | BMRN | TEM |
|---|---|---|
| Return on Equity (TTM) | 8.84% | -67.96% |
| Return on Assets (TTM) | 7.13% | -12.79% |
| Net Profit Margin (TTM) | 16.82% | -18.45% |
| Operating Profit Margin (TTM) | 19.89% | -23.00% |
| Gross Profit Margin (TTM) | 81.32% | 61.73% |
Financial Strength
Current Ratio (MRQ)
BMRN
4.83
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
BMRN’s Current Ratio of 4.83 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
TEM
3.28
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
TEM’s Current Ratio of 3.28 is in the upper quartile for the Life Sciences Tools & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
BMRN
0.10
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TEM
2.45
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.45, TEM operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
BMRN
-21.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
TEM
-14.08
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
TEM has a negative Interest Coverage Ratio of -14.08. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | BMRN | TEM |
|---|---|---|
| Current Ratio (MRQ) | 4.83 | 3.28 |
| Quick Ratio (MRQ) | 3.10 | 3.00 |
| Debt-to-Equity Ratio (MRQ) | 0.10 | 2.45 |
| Interest Coverage Ratio (TTM) | -21.18 | -14.08 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
TEM
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
TEM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
TEM
0.00%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
TEM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BMRN | TEM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BMRN
20.17
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
BMRN’s P/E Ratio of 20.17 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
TEM
--
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
P/E Ratio data for TEM is currently unavailable.
Price-to-Sales Ratio (TTM)
BMRN
3.39
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.39 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
TEM
10.69
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
TEM’s P/S Ratio of 10.69 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
BMRN
1.72
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
BMRN’s P/B Ratio of 1.72 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
TEM
27.61
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
At 27.61, TEM’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | BMRN | TEM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 20.17 | -- |
| Price-to-Sales Ratio (TTM) | 3.39 | 10.69 |
| Price-to-Book Ratio (MRQ) | 1.72 | 27.61 |
| Price-to-Free Cash Flow Ratio (TTM) | 12.71 | -- |